MARKET

ASRT

ASRT

Assertio Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7273
+0.0092
+1.28%
After Hours: 0.7520 +0.0247 +3.40% 19:14 11/12 EST
OPEN
0.7400
PREV CLOSE
0.7181
HIGH
0.7590
LOW
0.7010
VOLUME
1.39M
TURNOVER
--
52 WEEK HIGH
5.88
52 WEEK LOW
0.7010
MARKET CAP
58.68M
P/E (TTM)
-0.9510
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ASRT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ASRT News

  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.17h ago
  • PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
  • Zacks.5d ago
  • Assertio Therapeutics EPS in-line, misses on revenue
  • seekingalpha.6d ago
  • Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.6d ago

More

Industry

Pharmaceuticals
+0.28%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About ASRT

Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
More

Webull offers Assertio Therapeutics Inc (ASRT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.